Schonfeld Strategic Advisors LLC cut its stake in shares of Catalyst Biosciences, Inc. (NASDAQ:CBIO) by 84.5% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 13,500 shares of the biopharmaceutical company’s stock after selling 73,643 shares during the quarter. Schonfeld Strategic Advisors LLC’s holdings in Catalyst Biosciences were worth $58,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors also recently modified their holdings of CBIO. Stonepine Capital Management LLC boosted its stake in Catalyst Biosciences by 157.8% during the third quarter. Stonepine Capital Management LLC now owns 1,411,412 shares of the biopharmaceutical company’s stock worth $6,069,000 after acquiring an additional 863,871 shares in the last quarter. Nantahala Capital Management LLC lifted its stake in shares of Catalyst Biosciences by 25.9% in the second quarter. Nantahala Capital Management LLC now owns 1,821,749 shares of the biopharmaceutical company’s stock valued at $10,694,000 after buying an additional 375,000 shares in the last quarter. Alyeska Investment Group L.P. bought a new position in shares of Catalyst Biosciences in the second quarter valued at $1,284,000. BlackRock Inc. lifted its stake in shares of Catalyst Biosciences by 17.5% in the third quarter. BlackRock Inc. now owns 1,276,491 shares of the biopharmaceutical company’s stock valued at $5,489,000 after buying an additional 190,522 shares in the last quarter. Finally, M Holdings Securities Inc. bought a new position in shares of Catalyst Biosciences in the second quarter valued at $866,000. 60.52% of the stock is currently owned by institutional investors and hedge funds.
A number of research analysts have weighed in on CBIO shares. Lifesci Capital reaffirmed an “outperform” rating on shares of Catalyst Biosciences in a research note on Thursday, November 5th. Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $7.00 price target on the stock in a research report on Tuesday. ValuEngine upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating in a report on Monday, December 21st. Finally, Raymond James set a $20.00 price objective on shares of Catalyst Biosciences and gave the stock an “outperform” rating in a report on Tuesday, December 15th. Five research analysts have rated the stock with a buy rating, The stock currently has an average rating of “Buy” and a consensus price target of $15.00.
Catalyst Biosciences (NASDAQ:CBIO) last posted its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, topping the consensus estimate of ($0.81) by $0.08. The business had revenue of $0.89 million during the quarter. On average, research analysts predict that Catalyst Biosciences, Inc. will post -2.69 earnings per share for the current fiscal year.
About Catalyst Biosciences
Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing various treatments for hemophilia and other rare bleeding disorders using its potent subcutaneous (SQ) coagulation factors that promote blood clotting. Its engineered coagulation factors are designed to overcome the limitations of current intravenous (IV) treatment options, facilitate prophylaxis, and ultimately deliver substantially better outcomes for patients using SQ dosing.
Featured Story: What does a market perform rating mean?
Want to see what other hedge funds are holding CBIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Catalyst Biosciences, Inc. (NASDAQ:CBIO).
Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.